Twist Bioscienceは Q2 EPSが失敗し,収益の見積もりを超え,FY 2024の予測を上げました. Twist Bioscience reported Q2 EPS miss, exceeded revenue estimates, and raised FY 2024 guidance.

Twist Bioscience (TWST) は,EPS (1.47ドル) とコンセンサス推定 (0.76ドル) の Q2 の収益を報告したが,収益は8150万ドルで推定を超えた. Twist Bioscience (TWST) reported a Q2 earnings miss with EPS of ($1.47) vs. consensus estimate of ($0.76), but revenue of $81.5M exceeded estimates. 会社では2024年度と2024年第4四半期に EPSの予測を更新しました. The company updated its FY 2024 guidance for EPS and Q4 2024 guidance. 利益が落ちたにもかかわらず,NASDAQ:TWSTの株は2.36ドル上昇し,45.33ドルに達した. Despite the earnings miss, NASDAQ:TWST stock traded up $2.36, reaching $45.33. 内部情報提供者は 過去90日間で 11,289株を売却した Insiders have sold 11,289 shares in the past 90 days. JPMorgan,Evercore,Scotiabank,Guggenheim,TD Cowenのアナリストは価格目標と格付けの更新を発表した. Analysts at JPMorgan, Evercore, Scotiabank, Guggenheim, and TD Cowen provided updated price targets and ratings. 合成DNAベースの製品を製造販売するTwist Bioscience Corporationは,同年比27.7%の収益増加を記録しました. Twist Bioscience Corporation, which manufactures and sells synthetic DNA-based products, saw its revenue increase by 27.7% year-over-year.